This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


CellGenTech,Inc
【Field/Business】
Pharmaceutical/Drug Discovery
Drug discovery support/Contract service

last update:2017/5/1
Profile

Delegates :
Masayuki Aso


Incorporated :
October  20 , 2003

Paid in Capital :
35 Million yen  

Employees :
12 人

Address :
Chiba-dai Inohana Innovation Plaza 1-8-15, Inohana, Chuo-ku,Chiba-city CHIBA
〒260-0856

TEL/FAX :
+81-43-441-4121 / +81-43-441-4121

URL:
http://www.cellgentech.com/english/e_index.html

Attachment :

Mission/Background :
CellGenTech is a bio-venture company in close coordination with academia. We actively research and develop treatments by Gene/ Cell therapy technologies and regenerating medicine. Regenerating therapy, Cell/Gene therapy are expected to be the promising approaches in 21st century against intractable diseases. Cellgentech,Inc. dedicates to improve the quality of life of patients suffering from various incurable diseases through providing "therapeutic gene transduced human adipocyte".

Technology & Business
We have been developing “gene transduced adipocyte”using human adipocytes for sustained release of therapeutic protein, and have established the manufacturing process. We are continuing to expand our versatile technology to various intractable diseases, developing transduced adipocyte-based medicine to contribute to the benefit of patients suffered from various intractable diseases.“gene transduced adipocyte”possesses several features;Transgene can be maintained stably. Adipocytes have a low risk of transformation reportedly, and tumorigenesis of the transduced adipocytes was not observed. Adipocytes are adherent cells with less possibility to disseminate to other organs.Adipocytes have a long life span, allowing the long sustained supply of the therapeutic protein.Patent:“Primary cultured adipocytes for gene therapy”Cellgentech Inc. obtained the exclusive right for clinical use from Eisai Co.Patent
granted:U.S.A./EU/JPN
Products & Service
Products & Service Name
Stage
Outline
Milestone
Contribution to the treatment of familial LCAT deficiency
Preclinical
LCAT gene transduced adipocyte which can afford sustained release of LCAT to familial LCAT deficiency
Colaboration with pharmaceutical companies
transduced adipocytes for gene therapy to other rare and intractable diseases for Hemophilia and Fabry's diseases
Discovery
research with transduced adipocytes for gene therapy to rare and intractable diseases
Colaboration with pharmaceutical companies
transduced adipocytes for gene therapy for Rearch use only
Service/Marketing
provision of transduced adipocytes for gene therapy for Rearch use only









Highlights
Familial LCAT deficiency is a hereditary disease where the gene for is genetically deficient. FLD is a rare disease accompanied with dysfunction in eye or kidney. The LCAT gene transduced adipocyte is expected to afford sustained release of LCAT to FLD patients after the transplantation. The clinical research at Chiba University has been conducting from Aug. 2016, which was approved by MHLW Aug 2016 based on the law of the safe security methods such as regenerative medicine.
Hot news
The clinical research at Chiba University for Familial LCAT deficiency by the transplantation of LCAT gene transduced adipocyte has been conducting from Aug. 2016 based on the law of the safe security methods such as regenerative medicine.
Alliance strategy
Our “transduced adipocyte-based medicine” is focused on Congenital metabolic diseases by replacing deficient or reduced protein/enzyme, and Intractable chronic diseases by supplying of therapeutic recombinant protein to improve clinical condition. Our mission is to provide our new technology of “transduced adipocyte-based medicine" to the patients suffering from intractable diseases. We are actively seeking partners.


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.